71 deals worth $12.9B reported in May 2023: Global Data

The industry reported 97 venture capital (VC) deals worth $3 billion in May 2024, compared to the last 12-month (May 2023 to April 2024) average of 110 deals worth $2.7 billion

In May 2024, the healthcare industry reported 71 deals worth $12.9 billion, compared to the last 12-month (May 2023 to April 2024) average of 99 deals worth $19.2 billion.

Merck & Co, to acquire Eyebiotech, a clinical-stage ophthalmology biotechnology company, for a potential value of $3 billion; Biogen to acquire Human Immunology Biosciences, a biotechnology company, for a consideration of approximately $1.8 billion; and Novartis AG to acquire  Mariana Oncology, a preclinical-stage biotechnology company for an approximate consideration of $1.7 billion. These were the three major deals that contributed 51 per cent of the total deal value during May 2024.

The healthcare industry reported 97 venture capital (VC) deals worth $3 billion in May 2024, compared to the last 12-month (May 2023 to April 2024) average of 110 deals worth $2.7 billion.

AltruBio, a clinical stage biotechnology company raising $225 million in series B financing to advance the clinical development of novel immune checkpoint enhancer program; Zenas BioPharma (USA), a biopharmaceutical company, raising $200 million in series C financing to advance mid and late-stage immunology-focused clinical development programs; TheRas, d/b/a BridgeBio Oncology Therapeutics, raising $200 million in financing to accelerate the development of its novel precision oncology pipeline. These were the three major VC deals reported in May 2024.

AltruBioBiogenBridgeBio Oncology TherapeuticsEyebiotechglobal dataHealthcare industryHuman Immunology BiosciencesMariana OncologyMerck & CoNovartis AGVenture capitalZenas BioPharma
Comments (0)
Add Comment